Patient Characteristics
. | Value . |
---|---|
Age, median (range) | 11 y (2 mo to 23 y) |
Sex (N = 50), % of total | |
Male | 56 |
Female | 44 |
Diagnosis (N = 50), % of total | |
Cancer | 80 |
Leukemia | 26 |
CNS tumor | 14 |
Solid tumor | 40 |
Cystic fibrosis | 6 |
Seizure disorder | 6 |
Other | 8 |
Reason for use or potential use (>1 possible per patient), % of total | |
Nausea and vomiting | 40 |
Appetite stimulation | 36 |
Pain | 38 |
Seizures | 6 |
Anticancer | 20 |
Other | 14 |
Product used (N = 50), % of total | |
Tetrahydrocannabinol only | 6 |
Cannabidiol only | 20 |
Tetrahydrocannabinol and cannabidiol combination | 12 |
No product at time of consultation | 62 |
. | Value . |
---|---|
Age, median (range) | 11 y (2 mo to 23 y) |
Sex (N = 50), % of total | |
Male | 56 |
Female | 44 |
Diagnosis (N = 50), % of total | |
Cancer | 80 |
Leukemia | 26 |
CNS tumor | 14 |
Solid tumor | 40 |
Cystic fibrosis | 6 |
Seizure disorder | 6 |
Other | 8 |
Reason for use or potential use (>1 possible per patient), % of total | |
Nausea and vomiting | 40 |
Appetite stimulation | 36 |
Pain | 38 |
Seizures | 6 |
Anticancer | 20 |
Other | 14 |
Product used (N = 50), % of total | |
Tetrahydrocannabinol only | 6 |
Cannabidiol only | 20 |
Tetrahydrocannabinol and cannabidiol combination | 12 |
No product at time of consultation | 62 |
CNS, central nervous system.